In order to abrogate this response, we treated aged TBI mice with cenicriviroc (CVC), a potent, oral, dual-antagonist of CCR2/5, which is currently being evaluated in a phase 2 clinical trial in adults with non-alcoholic fatty liver disease and liver fibrosis (NCT02217475). This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatotic liver disease.